Sanofi's strategy head to retire by month end, as company gears up for December strategic update
While speculation that Sanofi is considering options for its consumer healthcare unit erupts ahead of a planned strategic update next month, it looks like the French drugmaker is losing a senior executive in charge of strategy.
Muzammil Mansuri, executive vice president of strategy, and business development — and member of Sanofi’s executive committee — is set to leave the company by the end of November, Reuters reported on Friday, citing an internal memo.
A Sanofi spokesperson confirmed the departure.
Mansuri, as planned, has decided to retire at the end of the month after playing a key role in reshaping the company’s strategy, overseeing acquisitions and structuring partnerships and alliances, the spokesperson told Endpoints News.
Mansuri started out as a research scientist at the energy company Shell before moving to Bristol-Myers. His last role prior to joining Sanofi in 2016 was senior VP of R&D strategy and corporate development at Gilead Sciences.
Alban de La Sabliere, currently Sanofi’s head of business development, and Laurent van Lerberghe, head of strategy, will expand their roles to take on alliance management, competitive intelligence, and Sanofi Ventures as well as portfolio analytics and corporate strategy, respectively, the spokesperson said.
Newly crowned chief executive Paul Hudson, who took charge of Sanofi on September 1, is set to address investors and offer a ‘strategic update’ for a capital markets day in Cambridge, Massachusetts on December 10. In preparation for the event, all of Sanofi’s businesses are undergoing a thorough review.
Hudson, who succeeded Olivier Brandicourt, inherited a company with a slipping stock price, a diabetes arm largely in decline due to US pricing pressures, and an R&D department that lags behind its compatriots, particularly after some key hiccups in oncology. In an interview with a gaggle of journalists last month, he hinted that the company is working on jazzing up its prospects in cancer and expanding its reach in China, expecting 30 drug launches in the region by 2025.